News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innate Pharma Updates on its Next Meetings with Analysts and Investors


3/23/2011 2:18:48 PM

Marseilles, France, March 23, 2011 -- Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that it will participate to the following analyst and investor conferences in the coming weeks:

- Benelux Midcap Event in Brussels, Belgium, on March 31 & April 1, 2011

- Paris Smallcap Event in Paris, France, on April 26 & 27, 2011

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company’s website (www.innate- pharma.com) and contact the investor relations team by writing to investors@innate- pharma.com.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting regulation pathways of innate immunity cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation currently in Phase II clinical trials in hematologic cancers. Two of its antibody programs in chronic inflammation are out- licensed to Novo Nordisk A/S.

Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 86 employees as at December 31, 2010.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code Ticker code FR0010331421 IPH

Disclaimer: This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma Alize Public Relations Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 investors@innate-pharma.com

Alize Public Relations Caroline Carmagnol Phone: +33 (0)1 41 22 07 31 Mobile: +33 (0)6 64 18 99 59 caroline@alizerp.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES